Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Cash from Financing Activities (2018 - 2025)

Serina Therapeutics (SER) has disclosed Cash from Financing Activities for 8 consecutive years, with $481000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 90.44% to $481000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $17.4 million through Dec 2025, up 31.79% year-over-year, with the annual reading at $17.4 million for FY2025, 31.79% up from the prior year.
  • Cash from Financing Activities hit $481000.0 in Q4 2025 for Serina Therapeutics, down from $6.4 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $10.1 million in Q1 2023 to a low of -$13000.0 in Q4 2023.
  • Historically, Cash from Financing Activities has averaged $2.7 million across 5 years, with a median of $1.9 million in 2021.
  • Biggest five-year swings in Cash from Financing Activities: tumbled 100.87% in 2023 and later soared 48890.91% in 2024.
  • Year by year, Cash from Financing Activities stood at $1.8 million in 2021, then decreased by 14.29% to $1.5 million in 2022, then crashed by 100.87% to -$13000.0 in 2023, then surged by 38800.0% to $5.0 million in 2024, then crashed by 90.44% to $481000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for SER at $481000.0 in Q4 2025, $6.4 million in Q3 2025, and $5.6 million in Q2 2025.